Some studies showed that patients with detectable EGFR T790M mutation had a shorter PFS, but this had no impact on OS, while others found that the presence of pre-treatment EGFR T790M mutation indicated favorable outcomes in advanced NSCLC patients treated with EGFR-TKIs [32,33,34,35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.